Carbon Dioxide for Coronary Artery Disease
(NIMO-CAD Trial)

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Indiana University

No Placebo Group

Trial Summary

What is the purpose of this trial?

This is a prospective pilot study to evaluate the safety, tolerability and technical feasibility of utilizing carbon dioxide for assessing coronary blood flow in subjects with coronary artery disease.

Eligibility Criteria

This trial is for individuals with coronary artery disease. Specific eligibility criteria are not provided, but typically participants would need to meet certain health conditions and agree to the study's procedures.

Inclusion Criteria

I am older than 18 years.

I have stable heart disease or it's suspected.

The SPECT/PET study indicates at least a mild to moderate myocardial ischemia (>5-9%) or fractional-flow-reserve (FFR) of <0.75.

Exclusion Criteria

Hypotension (systolic blood pressure < 100 mmHg)

Inability to voluntarily increase their breathing rate if prompted to do so

I have had a heart attack in the past.

See 12 more

Treatment Details

Interventions

RespirAct (Gas Therapy)

Trial OverviewThe trial is testing RespirAct, a method using carbon dioxide to assess blood flow in the coronary arteries. It's a pilot study focusing on how safe and feasible this technique is for patients with heart issues.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Coronary Artery Disease (CAD) SubjectsExperimental Treatment1 Intervention

Subjects with a of coronary artery disease will undergo computer-controlled gas challenges.